KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Gross Margin (2018 - 2025)

Historic Gross Margin for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to 77.48%.

  • Castle Biosciences' Gross Margin fell 43300.0% to 77.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.94%, marking a year-over-year decrease of 19600.0%. This contributed to the annual value of 81.87% for FY2024, which is 23400.0% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Gross Margin is 77.48%, which was down 43300.0% from 79.55% recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Gross Margin registered a high of 86.73% during Q1 2021, and its lowest value of 75.17% during Q4 2022.
  • Its 5-year average for Gross Margin is 80.12%, with a median of 80.96% in 2024.
  • As far as peak fluctuations go, Castle Biosciences' Gross Margin plummeted by -88600bps in 2022, and later skyrocketed by 60400bps in 2023.
  • Quarter analysis of 5 years shows Castle Biosciences' Gross Margin stood at 81.64% in 2021, then decreased by -8bps to 75.17% in 2022, then grew by 8bps to 81.21% in 2023, then rose by 0bps to 81.25% in 2024, then dropped by -5bps to 77.48% in 2025.
  • Its last three reported values are 77.48% in Q3 2025, 79.55% for Q2 2025, and 81.38% during Q1 2025.